Search this website. You can use fund codes to locate specific funds


Noting the company’s underperforming productivity in research and development and subsequently poor market rating at the time, our engagement with AstraZeneca was triggered by a share incentive scheme introduced in 2010. We voted against the scheme as its performance hurdles in dividend payments and dividend cover painted a bleak picture for the future of the business. Following this we met the company’s chair in 2011, which heightened our concerns on the company’s strategic direction and performance and left us questioning the quality of the board and the company’s leadership. AstraZeneca made headlines in 2014 for a takeover approach by Pfizer, which it rejected despite a substantial premium to the pre-bid price.

What we did
Shortly after the meeting with the chair, we raised our concerns with another board member and welcomed the news that the refreshment of the chair’s role would be brought forward. This was at the same time as the CEO announced his retirement from the AstraZeneca board, signalling the gravity of concerns about the company’s performance. We requested a meeting with the chair designate before he officially took up the role to put across our thoughts on the company and get a sense of his initial views on how to rebuild market confidence in AstraZeneca. We also continued our discussions with the remuneration committee chair on how to incentivise the new management to revive the business.

We have since met the chair and other board members on a regular basis and have been impressed by the new leadership and the turnaround AstraZeneca is undergoing. The company’s reinvigorated performance ultimately resulted in the board feeling confident enough to reject the takeover bid from Pfizer in 2014. We have gained helpful insights into the board’s considerations in this regard as well as its vision for the future of AstraZeneca. However it is crucial that its board and management are held accountable for the performance targets implicit in the company’s rejection of the bid. In addition, given the importance of intellectual property protection for AstraZeneca, we have discussed the issue of cyber security with the chair, who is also the chair of communications and technology services company Ericsson. Although this is a topic we will continue to pursue, we have been encouraged by more recent developments at the company in this area.

Related articles

Outlooks for the rest of 2022
Five Federated Hermes funds awarded Austrian EcoLabel
Spectrum Q2 2022: Investing into the aluminium paradox
Federated Hermes appoints Orla Garvey as Senior PM in Global Fixed Income team
Climate Change High Yield Credit strategy, interim report 2022
Public declaration of voting recommendations 2022

Sales contacts

Clive Selman, Executive Director - Head of Distribution, UK & Ireland